MX2016006584A - Métodos y composiciones para tratar los depósitos de amiloide. - Google Patents
Métodos y composiciones para tratar los depósitos de amiloide.Info
- Publication number
- MX2016006584A MX2016006584A MX2016006584A MX2016006584A MX2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- mammal
- amyloid deposits
- blood sample
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 5
- 239000008280 blood Substances 0.000 abstract 4
- 210000004369 blood Anatomy 0.000 abstract 4
- 101800001718 Amyloid-beta protein Proteins 0.000 abstract 3
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906811P | 2013-11-20 | 2013-11-20 | |
| PCT/US2014/066658 WO2015077473A1 (en) | 2013-11-20 | 2014-11-20 | Methods and compositions for treating amyloid deposits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006584A true MX2016006584A (es) | 2016-09-06 |
Family
ID=53180142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006584A MX2016006584A (es) | 2013-11-20 | 2014-11-20 | Métodos y composiciones para tratar los depósitos de amiloide. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170336395A1 (https=) |
| EP (1) | EP3071240B1 (https=) |
| JP (1) | JP6592435B2 (https=) |
| KR (1) | KR20160079891A (https=) |
| AU (1) | AU2014352944A1 (https=) |
| CA (1) | CA2931220A1 (https=) |
| ES (1) | ES2874704T3 (https=) |
| IL (1) | IL245703B (https=) |
| MX (1) | MX2016006584A (https=) |
| WO (1) | WO2015077473A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045347A1 (en) * | 2016-09-02 | 2018-03-08 | Spark Therapeutics, Inc. | Methods and vectors for treating cns disorders |
| EP3534892A4 (en) * | 2016-11-04 | 2020-05-27 | The Children's Hospital of Philadelphia | GENE TRANSFER COMPOSITIONS, METHODS AND USE FOR TREATING NEURODEGENERATIVE DISEASES |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| WO2021026495A1 (en) * | 2019-08-07 | 2021-02-11 | Texas Tech University System | Ad36e40rf1: a therapeutic treatment for alzheimer's disease |
| EP4045653A1 (en) * | 2019-10-16 | 2022-08-24 | Cornell University | Gene therapy for alzheimer's disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3002156A (en) * | 1961-09-26 | pumped solid state maser | ||
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| CA2457145C (en) * | 2001-08-17 | 2010-12-21 | Washington University | Assay method for alzheimer's disease |
| WO2004108922A2 (en) * | 2003-04-25 | 2004-12-16 | The Trustees Of The University Of Pennsylvania | Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver |
| WO2007022015A1 (en) * | 2005-08-12 | 2007-02-22 | Georgetown University | Methods to evaluate amyloid beta-lowering agents using wild-type mice |
| ES2373048T3 (es) * | 2006-06-08 | 2012-01-30 | Fu Berlin | Análisis para el diagnóstico de la enfermedad de alzheimer basado en la determinación de la proporción de productos de escisión ab de secretasa. |
| US20080234377A1 (en) * | 2007-03-23 | 2008-09-25 | Martek Biosciences Corporation | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| EP3066979B1 (en) * | 2010-05-24 | 2017-11-01 | The Washington University | Methods of determining amyloid beta turnover in blood |
| ES2745470T3 (es) * | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| EP2511296A1 (en) * | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| AU2012282825B2 (en) * | 2011-07-13 | 2016-05-26 | Merck Sharp & Dohme Corp. | Method for detection of amyloid beta oligomers in a fluid sample and uses thereof |
-
2014
- 2014-11-20 MX MX2016006584A patent/MX2016006584A/es unknown
- 2014-11-20 CA CA2931220A patent/CA2931220A1/en not_active Abandoned
- 2014-11-20 IL IL245703A patent/IL245703B/en unknown
- 2014-11-20 WO PCT/US2014/066658 patent/WO2015077473A1/en not_active Ceased
- 2014-11-20 JP JP2016532124A patent/JP6592435B2/ja active Active
- 2014-11-20 KR KR1020167016073A patent/KR20160079891A/ko not_active Ceased
- 2014-11-20 AU AU2014352944A patent/AU2014352944A1/en not_active Abandoned
- 2014-11-20 EP EP14863892.7A patent/EP3071240B1/en active Active
- 2014-11-20 US US15/038,367 patent/US20170336395A1/en not_active Abandoned
- 2014-11-20 ES ES14863892T patent/ES2874704T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016540977A (ja) | 2016-12-28 |
| IL245703A0 (en) | 2016-07-31 |
| EP3071240A4 (en) | 2017-10-11 |
| ES2874704T3 (es) | 2021-11-05 |
| BR112016011258A2 (pt) | 2017-09-26 |
| US20170336395A1 (en) | 2017-11-23 |
| AU2014352944A1 (en) | 2016-06-16 |
| JP6592435B2 (ja) | 2019-10-16 |
| IL245703B (en) | 2022-07-01 |
| CA2931220A1 (en) | 2015-05-28 |
| WO2015077473A1 (en) | 2015-05-28 |
| EP3071240B1 (en) | 2021-01-06 |
| EP3071240A1 (en) | 2016-09-28 |
| KR20160079891A (ko) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| SG10201804505VA (en) | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| MX2018008882A (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| PH12016501051A1 (en) | Methods of treasting and preventing alloantibody driven chronic graft versus host disease | |
| MX2023002021A (es) | Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune. | |
| BR112015027477A8 (pt) | bolus, seus usos, e kit | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| MX2016006584A (es) | Métodos y composiciones para tratar los depósitos de amiloide. | |
| MX2018000528A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| TR201900665T4 (tr) | Diyabetik nefropatinin tedavi yöntemi. | |
| WO2014169011A3 (en) | Methods for treating immune diseases | |
| MX2018001493A (es) | Gdf-15 como biomarcador de toxicidad hematologica. | |
| MX2015011371A (es) | Anticuerpos monoclonales anti-+)--metanfetamina. |